ArticleSurgical endoscopy2016
Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.
Article in Surgical endoscopy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03222635 (Endoscopic Management of Patients With High Risk T1a and T1b N0M0 Esophageal Adenocarcinoma), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Endoscopic Management of Patients With High Risk T1a and T1b N0M0 Esophageal Adenocarcinoma: a Prospective Multicenter Registry.
Who cites it
32 citing papers in PubMed, 84 citations in OpenAlex.
- Evolving challenges in the management of early esophageal adenocarcinoma: from clinical staging to molecular insights.World journal of surgical oncology · 2026Review
- Outcomes after radical endoscopic resection of high risk T1 esophageal adenocarcinoma: an international multicenter retrospective cohort study.Endoscopy · 2025Article
- Reassessment reveals underestimation of infiltration depth in surgical resection specimens with lymph-node positive T1b esophageal adenocarcinoma.Endoscopy international open · 2025Article
- Reasons for fear of cancer recurrence after endoscopic treatment of T1 esophageal adenocarcinoma. A semi-structured interview study.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2024Article
- Special requirements for TNM-staging in esophageal cancer.Journal of thoracic disease · 2024Article
- History and evidence for state of the art of lymphadenectomy in esophageal cancer surgery.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2024Review
- Latest Advances in Endoscopic Detection of Oesophageal and Gastric Neoplasia.Diagnostics (Basel, Switzerland) · 2024Review
- Feasibility and Safety of Tailored Lymphadenectomy Using Sentinel Node-Navigated Surgery in Patients with High-Risk T1 Esophageal Adenocarcinoma.Annals of surgical oncology · 2023Article
- Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review.Cancers · 2023Review
- The 8th Wonder of the Cancer World: Esophageal Cancer and Inflammation.Diseases (Basel, Switzerland) · 2022Review
- Today's Mistakes and Tomorrow's Wisdom… in the Management of T1b Barrett's Adenocarcinoma.Visceral medicine · 2022Review
- Today's Mistakes and Tomorrow's Wisdom in the Surgical Treatment of Barrett's Adenocarcinoma.Visceral medicine · 2022Review
- Feasibility of sentinel node navigated surgery in high-risk T1b esophageal adenocarcinoma patients using a hybrid tracer of technetium-99 m and indocyanine green.Surgical endoscopy · 2022Article
- Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.World journal of gastrointestinal oncology · 2022Review
- A population-based investigation: How to identify high-risk T1-2N0 esophageal cancer patients?Frontiers in surgery · 2022Article
- Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.Gastrointestinal endoscopy · 2020Article
- Radiofrequency Ablation of Barrett's Esophagus: Have We Gone Too Far, or Not Far Enough?Current gastroenterology reports · 2020Review
- Infiltration Depth is the Most Relevant Risk Factor for Overall Metastases in Early Esophageal Adenocarcinoma.World journal of surgery · 2020Article
- Quality indicators for Barrett's endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett's neoplasia.Frontline gastroenterology · 2020Article
- Resection of early esophageal neoplasms: The pendulum swings from surgical to endoscopic management.World journal of gastrointestinal endoscopy · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophagectomy for submucosal (T1b) esophageal adenocarcinoma (EAC) is performed in order to optimize patient outcomes given the risk of concurrent lymph node metastases (LNM). However, not seldom, comorbidity precludes these patients from surgery. Therefore, the aim of our study was to assess the course of follow-up after treatment in submucosal EAC patients undergoing surgery versus conservative therapy and to evaluate the incidence of metastatic disease.
methodsBetween 2001 and 2012, all patients undergoing diagnostic endoscopic resection for EAC in two centers were reviewed. Only patients with histopathologically proven submucosal tumor invasion were included. Submucosal EACs were divided into tumors that were removed radically (R0) and irradically (R1). Subsequently, in the R0 group, EACs were classified as either low risk (LR; submucosal invasion <500 nm, G1-G2, no LVI) or high risk (HR; deep submucosal invasion >500 nm, G3-G4 and/or LVI). Metastatic disease was defined as LNM in surgical resection specimen and/or evidence of malignant disease during follow-up (FU).
resultsSixty-nine patients with a submucosal EAC were included [23 R1-resections and 46 R0-resection (14 R0-LR and 32 R0-HR)]. Twenty-six patients underwent surgical treatment (1 R0-LR, 12 R0-HR and 13 R1). None of the 14 R0-LR patients developed metastatic disease after a median FU of 60 months. In the R0-HR group and R1 group, metastatic disease was diagnosed in 16 and 30 % of patients, respectively. Surgical patients tended to have a better overall survival than non-surgical patients (p = 0.09). Tumor-related deaths, however, were 12 % in both groups.
conclusionsIn LR submucosal EAC, the risk of metastatic disease appears to be very low. In deep submucosal EAC (either R0- or R1-resection), the rate of metastatic disease is lower than reported in earlier surgical series. Given the reasonable disease-free survival and high background mortality, conservative management of these patients seems to be a valid alternative for surgery in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.